Learn if You Have a Claim Against Schering-Plough & Merck

Zetia and Vytorin Personal Injury and Out of Pocket Expense Investigation

KGS is investigating lawsuits related to the cholesterol-lowering drugs Zetia (ezetimibe) and Vytorin (a combination of ezetimibe and simvastatin). Zetia was introduced in 2002, and by 2003, it was on the list of top-selling drugs with more than 4.2 million prescriptions written that year. The combination drug Vytorin was introduced one year later, in 2004, but the FDA reviewer of Vytorin recommended against approval of Vytorin. (For excerpts of the recommendation, see www.worstpills.org/public/newsletter.cfm?n_id=353)

Please explain any problems you have had in relation to this case:

Personal Information

First Name

Last Name

Street / Apt /

City, State Zip

Home Phone & Evening Phone (Same) . . & . .

E-Mail Address

Confirm E-Mail

Date Issue/Problem

Terms & Conditions
I acknowledge that I have read and understand and agree to the following legal policies.

Certain features of Lawcash.com require a login - please simply choose a password to continue.

Password

Confirm Password

I'd like to become a Lawcash.com member, receive a free class action ebook, and free class action and recall alerts. Billions of dollars are available each year and I'd like to claim my fair share from bad corporations.

Submit

Other Drugs / Medical Cases of Interest

Lawyers File Lawsuit Over Kaiser Permanente Kidney-Transplant Program

Lawyers filed a class-action lawsuit against Kaiser Permanente on behalf of patients of the HMO's troubled kidney-transplant program, which shut down in May 2006 amid federal and state investigations. The complaint, filed in San Francisco Superior Court, accuses Kaiser of fraud, negligence and mismanagement in its ability to properly administer the kidney transplant program, which included 2,000 patients in Northern California.

Adolor Allegedly Hid Failures of New Drug Entereg, Harming Investors

Several class actions have been filed against biopharmaceutical corporation Adolor Corporation (Nasdaq:ADLR) and certain of its officers and directors by stockholders who purchased the company's common stock between September 23, 2003, and January 14, 2004. The actions claim that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities.

Arkansas Teacher Retirement System Claims Drug Testing Company Violated Procedures in Clinical Trials

The Arkansas Teacher Retirement System filed a class action lawsuit against SFBC International, a drug testing company accused of violating regulatory procedures in administering clinical trials.

Intermune to Pay $37 Million for Promotion of Actimmune Drug

InterMune Inc., a biopharmaceutical company based out of California, has agreed to pay the government $36.9 million to resolve criminal charges and civil liabilities in connection with allegations of illegally promoting Actimmune for treatment of idiopathic pulmonary fibrosis (IPF).

Cold Remedies Zicam and Cold-Eeze Linked to Loss of Ability to Smell and Taste

Kahn Gauthier Swick is seeking persons who have used over-the-counter homeopathic nasal solutions Zicam or Cold-Eeze, and who have suffered an intense burning sensation in their nasal cavities immediately after using either of the products followed by a loss of smell and taste long after they were over their cold. If you or a loved one has used either of these preparations, please contact Kahn Gauthier for more information.

Union Prescription Plan Joins Tidal Wave of Consumer Plaintiffs Suing Pfizer Over Aggressive Marketing of Epilepsy Drug for Questionable Off-Label Use

Yet another class action has been filed against pharmaceutical manufacturer Pfizer, Inc., and Warner-Lambert Company over its questionable, but highly lucrative marketing of the epilepsy drug Neurontin (gabapentin), for off-label uses. This latest action is brought by the International Union of Operating Engineers Local No. 68 Welfare Plan on behalf of all U.S. consumers who paid some or all of the cost of an off-label-use Neurontin prescription since 1994. The Union claims that its prescription drug coverage plan incurred substantial costs for Neurontin prescriptions, the vast majority of which were for conditions other than epilepsy, the official FDA use for the drug. Plaintiffs allege that Pfizer has harmed consumers by conspiring to circumvent drug approval regulations set up by the U.S. Food and Drug Administration (FDA), and promoting scientifically unproven "off-label" use of Neurontin, in violation of the federal Racketeer Influenced and Corrupt Organizations Act. The action seeks unspecified compensatory and triple punitive damages.